


Conjugate Vaccines


Eleonore Duroyon, Céline van Haaren and Juliette Margaria



Immune response to pathogens




Conjugate vaccine generates a T cell dependent response



Subunit vaccine: polysaccharide (PS)

T cell independent response

- **Weak** immune response
- Antibody has **low** affinity for antigen
- No memory cells generated




Conjugate vaccine: PS + antigenic protein

T cell dependent response

- **Strong** immune response
- Antibody has **high** affinity for antigen
- Memory cells generated

Haemophilus influenzae

- One of the leading causes of invasive bacterial infection in young children worldwide
- First conjugate vaccines extensively used
- Gram negative bacteria




Disease

- severe pneumonia and meningitis

Composition of the capsule and virulence


- 6 distinct capsular serotypes: a,b,c,d,e,f
 - type b is most virulent
- special cap: cap b (DNA duplication)



Virulence Factors

- polyribitol ribose phosphate
- polysaccharide(PRPs)
- lipooligosaccharide (LOS)
- alternating expression of pili

Composition vaccines



Vaccine	Polysaccharide Size	Carrier Protein	Linkage
PRP-D	Medium	Diphtheria Toxoid	6-carbon
HbOC	Small	Diphtheria Toxoid Mutant	None
PRP-OMP	Medium	N meningitidis outer membrane protein	Thioether
PRP-T	Large	Tetanus toxoid	6-carbon

Campylobacter jejuni

- Most common bacterial cause of enterogastritis in humans
- Encapsulated, Gram negative, zoonotic, invade the intestinal epithelium

Disease


symptoms : acute diarrhea, fever, and abdominal pain

Post infectious serious sequelae

mimicry of the outer lipooligosaccharide (LOS) regions =>
Guillain-Barré syndrome

Capsule and virulence

47 different serotypes (HS1, HS2, and HS4 most common
50% of the strains, HS 23/36 common in developing
countries)




- ~ Capsule → major serodeterminant
- ~ lipooligosaccharide (LOS)
- ~ Flagella → colonization

hyperendemic:
40% children
affected in
developing
regions of the
world


Composition vaccines

- no licensed vaccines → 2 prototypes
- against strains without mimicry



Symbols: triangles, 1 µg; squares, 5 µg; filled circles, 25 µg; open circles, PBS.


=> Long-Term protection



Symbols: diamonds, PBS; squares, 5 µg; circles, 25 µg.

=> Immunogenicity

Discussion & Limits



References

Agrawal, A. and Murphy, T. (2011). *Haemophilus influenzae* Infections in the *H. influenzae* Type b Conjugate Vaccine Era. *Journal of Clinical Microbiology*, 49(11), pp.3728-3732.

Cox, R. (2013). Correlates of protection to influenza virus, where do we go from here?. *Human Vaccines & Immunotherapeutics*, 9(2), pp.405-408.

Decker, M. and Edwards, K. (1998). *Haemophilus influenzae* type b vaccines: history, choice and comparisons. *The Pediatric Infectious Disease Journal*, 17(Supplement), pp.S113-S116.

Guerry, P., Poly, F., Riddle, M., Maue, A., Chen, Y. and Monteiro, M. (2012). *Campylobacter* Polysaccharide Capsules: Virulence and Vaccines. *Frontiers in Cellular and Infection Microbiology*, 2.

Iskander, M., Hayden, K., Van Domselaar, G. and Tsang, R. (2017). First Complete Genome Sequence of *Haemophilus influenzae* Serotype a. *Genome Announcements*, 5(3).

Kelly, D., Moxon, E. and Pollard, A. (2004). *Haemophilus influenzae* type b conjugate vaccines. *Immunology*, 113(2), pp.163-174.

MacLennan, C. (2013). Vaccines for low-income countries. *Seminars in Immunology*, 25(2), pp.114-123.

Maue, A., Poly, F. and Guerry, P. (2014). A capsule conjugate vaccine approach to prevent diarrheal disease caused by *Campylobacter jejuni*. *Human Vaccines & Immunotherapeutics*, 10(6), pp.1499-1504.

Merino, S. (2015). Bacterial Capsules and Evasion of Immune, 1–10. <https://doi.org/10.1002/9780470015902.a0000957.pub4>

Monteiro, M., Baqar, S., Hall, E., Chen, Y., Porter, C., Bentzel, D., Applebee, L. and Guerry, P. (2008). Capsule Polysaccharide Conjugate Vaccine against Diarrheal Disease Caused by *Campylobacter jejuni*. *Infection and Immunity*, 77(3), pp.1128-1136.

Plotkin, S., Orenstein, W. and Offit, P. (2013). *Vaccines*. [Edinburgh]: Elsevier/Saunders.

Riddle, M. and Guerry, P. (2016). Status of vaccine research and development for *Campylobacter jejuni*. *Vaccine*, 34(26), pp.2903-2906.